<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589602</url>
  </required_header>
  <id_info>
    <org_study_id>CCF-6501</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT00589602</nct_id>
  </id_info>
  <brief_title>T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases</brief_title>
  <official_title>Phase II Feasibility Study of T-Cell Depletion in Allogeneic Unrelated Bone Marrow Transplantation (MUD ALLO BMT) Followed by Delayed T-Cell Infusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood
      stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the
      patient's immune system from rejecting the donor's stem cells. When stem cells from a donor
      are infused into the patient they may help the patient's bone marrow make stem cells, red
      blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor
      can make an immune response against the body's normal cells. Removing the T cells from the
      donor cells before transplant may stop this from happening. Giving an infusion of the donor's
      T cells (donor lymphocyte infusion) after the transplant may help destroy any remaining
      cancer cells (graft-versus-tumor effect).

      PURPOSE: This phase II trial is studying T-cell depletion in donor stem cell transplant
      followed by delayed T cell infusions in treating patients with hematologic cancer or other
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine if T-cell depletion of a peripheral blood progenitor cell (PBPC) graft
           followed by delayed add-backs of defined doses of donor lymphocytes decreases the rate
           of graft-versus-host disease and its complications in matched unrelated donor (MUD)
           allogeneic peripheral blood progenitor cell (PBPC) transplantation in patients with
           hematologic cancers or other diseases.

        -  Determine whether targeted T-cell dosages in the PBPC graft can be achieved in these
           patients by positive CD34+ selection using the Baxter Inc. Isolex 300i v. 2.5.

        -  Determine the effects of T-cell depletion on the rate of engraftment in these patients.

        -  Develop a matched unrelated donor (MUD) allogeneic transplantation regimen that will
           decrease overall treatment-related mortality in these patients.

      OUTLINE: This is a non-randomized study.

        -  Myeloablative preparative regimen: Patients receive cyclophosphamide IV once daily on
           days -5 and -4 followed by total body irradiation twice daily on days -3, -2, and -1.
           Patients also receive tacrolimus on day -1 administered by continuous IV infusion over
           24 hours.

        -  Peripheral blood progenitor cell graft transplantation: Patients receive T-cell
           depleted, peripheral blood progenitor cells (PBPC) by IV infusion on day 0. Beginning 1
           day after completion of the PBPC infusion, patients receive filgrastim (G-CSF)
           subcutaneously once daily until blood counts recover.

        -  Post transplantation T cell add-backs: Patients receive defined doses of donor T cells
           by IV infusion on days 45 and 100, in the absence of active graft-versus-host disease
           (GVHD) requiring steroids*.

      NOTE: *A T cell add-back may be given in the presence of GVHD, if the investigator considers
      the risk from relapse or overwhelming viral infection to outweigh the risk of exacerbating
      GVHD.

      Patients will be followed periodically for relapse and survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Mortality (TRM)</measure>
    <time_frame>180 days after transplant</time_frame>
    <description>The complication rate in matched unrelated donor (MUD) allogeneic bone marrow transplant (allo BMT) is known to be high. Graft failure and severe graft versus host disease (GvHD) are the most significant contributors to treatment related mortality (TRM). This treatment regimen will be considered unacceptable if the number of patients that experience TRM is 55% or greater, and effective if TRM is 33% or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Rate of Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>D+100 from transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Duration of Absolute Neutropenia</measure>
    <time_frame>D+100 from transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Able to Receive T-cell Add Backs</measure>
    <time_frame>through D+100</time_frame>
    <description>Patients receive defined doses of donor T cells by IV infusion on days 45 and 100, in absence of active graft-versus-host disease (GVHD) requiring steroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Relapse-free Survival</measure>
    <time_frame>after 7 years of follow up</time_frame>
    <description>number of patients that were still alive and relapse free</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Malignant Plasma Cell Neoplasms</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>T-Cell Depletion Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood lymphocyte therapy</intervention_name>
    <description>T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be &gt;0.5 x 105 but &lt;1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be &gt;2 x 106 cells/kg.</description>
    <arm_group_label>T-Cell Depletion Transplant</arm_group_label>
    <other_name>T-cell depletion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Allogeneic Hematopoietic Stem Cell Transplantation</description>
    <arm_group_label>T-Cell Depletion Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Peripheral blood stem cell transplantation</description>
    <arm_group_label>T-Cell Depletion Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation (TBI)</intervention_name>
    <description>Treatment will be delivered using 6MV photons twice daily for 3 days</description>
    <arm_group_label>T-Cell Depletion Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of any of the following hematologic cancers or other diseases:

               -  Acute myelogenous leukemia

                    -  Relapsed or refractory disease with poor-risk cytogenetics

               -  Acute lymphoblastic leukemia

                    -  Relapsed or refractory disease with poor-risk cytogenetics

               -  Chronic myelogenous leukemia

                    -  Persistent disease after at least 6 months of treatment with imatinib
                       mesylate (Gleevec)

               -  Myelodysplasia, meeting 1 of the following criteria:

                    -  French-American-British Classification of refractory anemia with excess
                       blasts (RAEB) or RAEB with transformation

                    -  International Prognostic Scoring System score &gt; 2

               -  Lymphoid malignancies, including non-Hodgkin lymphoma, Hodgkin disease, chronic
                  lymphocytic leukemia, and prolymphocytic leukemia

                    -  Relapsed or refractory disease after at least 1 prior therapy

               -  Myelofibrosis

                    -  Transfusion dependent (RBC's, platelets, or both)

               -  Paroxysmal nocturnal hemoglobinuria (transfusion dependent)

               -  Myeloproliferative disorder

               -  Eosinophilic leukemia

               -  Severe aplastic anemia

                    -  Corrected reticulocyte count &lt; 1%

                    -  Platelet count &lt; 30,000/mm³ (untransfused)

                    -  Bone marrow biopsy with &lt; 15% cellularity

               -  Plasma cell leukemia

          -  No essential thrombocytopenia or polycythemia vera

          -  No matched related donor available

          -  Must have an 8/8 or 7/8 serologic HLA matched unrelated donor available

        PATIENT CHARACTERISTICS:

          -  Cardiac ejection fraction ≥ 45% (if &lt; 45%, then cardiac consult required)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  FEV_1 and DLCO ≥ 45% predicted

          -  Creatinine &lt; 2.0 mg/dL

          -  Bilirubin &lt; 2.0 mg/dL

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior allogeneic bone marrow transplantation

          -  No concurrent administration of steroids with T-cell add-backs

        INCLUSION CRITERIA:

          -  Patient actual weight must not be greater than 1.5x their ideal body weight

          -  Cardiac ejection fraction &gt;45%. If less than 45%, a Cardiac consult will be obtained.

          -  A suitably matched unrelated donor that is at least a 7 out of 8 HLA serologic match.

          -  Patient is not pregnant.

          -  FEV 1 and DLCO &gt; 45% predicted on pulmonary function testing.

          -  Serum creatinine &lt;2.0 mg/dl, serum bilirubin &lt;2.0 mg/dl.

          -  Patient and donor are HIV negative.

          -  Diagnosis of one of the following diseases

          -  Acute myelogenous leukemia

          -  Relapsed disease,

          -  Refractory disease, or

          -  With poor-risk cytogenetics

          -  Acute lymphoblastic leukemia

          -  Relapsed disease,

          -  Refractory disease, or

          -  With poor-risk cytogenetics

          -  Chronic myelogenous leukemia

          -  Persistent disease after at least 6 months of treatment with Imatinib Mesylate
             (Gleevec)

          -  Myelodysplasia

          -  FAB Classification of RAEB or RAEB-T -Or-

          -  IPSS score &gt;2

          -  Lymphoid malignancies, including non-Hodgkin's lymphoma, Hodgkin's disease, chronic
             lymphocytic leukemia and prolymphocytic leukemia

          -  Relapsed or refractory disease after at least 1 prior therapy

          -  Myelofibrosis

          -  Transfusion dependence (RBC's, platelets, or both)

          -  Paroxysmal Nocturnal Hemoglobinuria (PNH)

          -  Transfusion dependent

          -  Myeloproliferative Disorder

          -  Eosinophilic Leukemia

          -  Severe aplastic anemia (&lt;1% corrected reticulocyte count, &lt;30,000 untransfused
             platelet count, bone marrow biopsy with &lt;15% cellularity)

          -  Plasma cell leukemia

          -  Patients with ET or PV will not be candidates unless their disease has transformed to
             end stage myelofibrosis or acute leukemia, for which eligibility criteria for
             myelofibrosis or acute leukemia would apply.

          -  Patient must signed written informed consent.

        EXCLUSION CRITERIA:

          -  Inability to give informed consent

          -  Absence of any of the above mentioned medical conditions

          -  Availability of matched-related donor

          -  History of prior allogeneic BMT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J. Bolwell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jarek Maciejewski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2008</study_first_submitted>
  <study_first_submitted_qc>January 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>September 20, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Jaroslaw Maciejewski</investigator_full_name>
    <investigator_title>Department Chair of Translational Hematology and Oncology Research</investigator_title>
  </responsible_party>
  <keyword>Adult leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>plasma cell disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from local hospital from January, 2006 through January, 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>T-Cell Depletion Transplant</title>
          <description>Our protocol is designed to attempt to improve the current results of MUD allo BMT and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'
peripheral blood lymphocyte therapy: T-cell depletion
cyclophosphamide: T-cell depletion
tacrolimus: T-cell depletion
allogeneic hematopoietic stem cell transplantation: T-cell depletion
peripheral blood stem cell transplantation: T-cell depletion
total-body irradiation: T-cell depletion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not collect enough CD34+ cells</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-Cell Depletion Transplant</title>
          <description>Our protocol is designed to attempt to improve the current results of MUD allo BMT and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'
peripheral blood lymphocyte therapy: T-cell depletion
cyclophosphamide: T-cell depletion
tacrolimus: T-cell depletion
allogeneic hematopoietic stem cell transplantation: T-cell depletion
peripheral blood stem cell transplantation: T-cell depletion
total-body irradiation: T-cell depletion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="18" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Mortality (TRM)</title>
        <description>The complication rate in matched unrelated donor (MUD) allogeneic bone marrow transplant (allo BMT) is known to be high. Graft failure and severe graft versus host disease (GvHD) are the most significant contributors to treatment related mortality (TRM). This treatment regimen will be considered unacceptable if the number of patients that experience TRM is 55% or greater, and effective if TRM is 33% or less.</description>
        <time_frame>180 days after transplant</time_frame>
        <population>Patients that received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>T-Cell Depletion Transplant</title>
            <description>Our protocol is designed to attempt to improve the current results of MUD allo BMT and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'
peripheral blood lymphocyte therapy: T-cell depletion
cyclophosphamide: T-cell depletion
tacrolimus: T-cell depletion
allogeneic hematopoietic stem cell transplantation: T-cell depletion
peripheral blood stem cell transplantation: T-cell depletion
total-body irradiation: T-cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality (TRM)</title>
          <description>The complication rate in matched unrelated donor (MUD) allogeneic bone marrow transplant (allo BMT) is known to be high. Graft failure and severe graft versus host disease (GvHD) are the most significant contributors to treatment related mortality (TRM). This treatment regimen will be considered unacceptable if the number of patients that experience TRM is 55% or greater, and effective if TRM is 33% or less.</description>
          <population>Patients that received treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Acute Graft Versus Host Disease (GVHD)</title>
        <time_frame>D+100 from transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-Cell Depletion Transplant</title>
            <description>Our protocol is designed to attempt to improve the current results of matched unrelated donor allogeneic bone marrow transplant (MUD allo BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; allogeneic hematopoietic stem cell transplantation;
peripheral blood lymphocyte therapy: T-cell depletion
cyclophosphamide: T-cell depletion
tacrolimus: T-cell depletion
allogeneic hematopoietic stem cell transplantation: T-cell depletion
peripheral blood stem cell transplantation: T-cell depletion
total-body irradiation: T-cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Acute Graft Versus Host Disease (GVHD)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Duration of Absolute Neutropenia</title>
        <time_frame>D+100 from transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-Cell Depletion Transplant</title>
            <description>peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be &gt;0.5 x 105 but &lt;1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be &gt;2 x 106 cells/kg.
cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day –5 and Day –4
tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours
allogeneic hematopoietic stem cell transplantation
peripheral blood stem cell transplantation
total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Duration of Absolute Neutropenia</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Able to Receive T-cell Add Backs</title>
        <description>Patients receive defined doses of donor T cells by IV infusion on days 45 and 100, in absence of active graft-versus-host disease (GVHD) requiring steroids.</description>
        <time_frame>through D+100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-Cell Depletion Transplant</title>
            <description>peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be &gt;0.5 x 105 but &lt;1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be &gt;2 x 106 cells/kg.
cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day –5 and Day –4
tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours
allogeneic hematopoietic stem cell transplantation
peripheral blood stem cell transplantation
total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Able to Receive T-cell Add Backs</title>
          <description>Patients receive defined doses of donor T cells by IV infusion on days 45 and 100, in absence of active graft-versus-host disease (GVHD) requiring steroids.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Relapse-free Survival</title>
        <description>number of patients that were still alive and relapse free</description>
        <time_frame>after 7 years of follow up</time_frame>
        <population>All patients that received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>T-Cell Depletion Transplant</title>
            <description>peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be &gt;0.5 x 105 but &lt;1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be &gt;2 x 106 cells/kg.
cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day –5 and Day –4
tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours
allogeneic hematopoietic stem cell transplantation
peripheral blood stem cell transplantation
total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse-free Survival</title>
          <description>number of patients that were still alive and relapse free</description>
          <population>All patients that received treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data was over the course of the study for approximately 7 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T-Cell Depletion Transplant</title>
          <description>peripheral blood lymphocyte therapy: T-cell depletion
cyclophosphamide: T-cell depletion
tacrolimus: T-cell depletion
allogeneic hematopoietic stem cell transplantation: T-cell depletion
peripheral blood stem cell transplantation: T-cell depletion
total-body irradiation: T-cell depletion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death by Relapse</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Death from Acute GVHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death due to Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for TTP (Thrombotic Thrombocytopenic Purpura)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for chest pains</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized with hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for blood in stool and</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for fever</sub_title>
                <counts group_id="E1" events="24" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized with GVHD</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for Nausae, Vomiting and Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for broken leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for Syncope and dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for puritus and plolyarthagias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for relapse of disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for numbness in hands and feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalized with Infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for a motor vehicle accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for necrosis of knees</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized with mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for mucocitus and rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for knee replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hospitalized for surgery medial epicondylitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jarek Maciejewski, MD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-5962</phone>
      <email>maciejj@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

